Skip to main content

Table 5 Grade 3–4 Adverse events occurring in patients

From: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

Adverse event mFOLFIRINOX (n = 27)
N (%)
Gemox (n = 22)
N (%)
p value
Neutropenia 13 (48.1) 8 (36.4) 0.407
Febrile neutropenia 3 (11.1) 0 0.107
Anemia 1 (3.7) 2 (9.1) 0.434
Thrombocytopenia 0 1 (4.5) 0.263
Vomiting 7 (25.9) 1 (4.5) 0.044
Diarrhea 3 (11.1) 0 0.107
Peripheral neuropathy 2 (7.4) 3 (13.6) 0.474
Fatigue 1 (3.7) 0 0.362
  1. Bold values are statistically significant (p ≤ 0.05)